Sun Starts Integration Of GSK's Opiates Business
This article was originally published in Scrip
Sun Pharmaceutical Industries has started the integration of its opiates business in Australia, acquired earlier this year from GlaxoSmithKline, following the completion of the deal.
You may also be interested in...
Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.